OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Full Issue PDF	155
Priorities in Cardio-Oncology	147
Balancing Promise and Evidence	117
Atrial Fibrillation in Patients With Cancer	98
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	91
Full Issue PDF	91
Full Issue PDF	88
Epigenomics of Cardio-Oncology	81
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	75
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	70
Hormonal Therapy and Cardiovascular Health	69
Cardiovascular Safety in Oncology Clinical Trials	68
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	68
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors	62
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	61
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	60
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	53
Full Issue PDF	52
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	52
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	48
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	47
Frailty	46
Cardiac Risk Stratification Before Lung Cancer Radiation	46
Proactive Surveillance for ICI Cardiotoxicity	45
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	40

Incretin Mimetics in Cancer and Cardiovascular Disease	40
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	39
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	38
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	37
Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations	37
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	37
Editorial Board/Officers Page	36
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	35
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	34
Atrial Fibrillation After Stem Cell Transplantation	34
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	32
Cancer Immunotherapy Beyond Checkpoint Blockade	32
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	32
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	31
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	31
Full Issue PDF	30
Permissive Cardiotoxicity	29
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	29
Developing a Model for Cross-Institutional Educational Collaborations	28
Full Issue PDF	28
Reply	28
Leveling Up	28
Editorial Board	28
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	28
Endothelin-1	27
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	27
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	26
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	26
Quality-of-Care Measures for Cardio-Oncology	25
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	25
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	25
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	25
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	24
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	24
The United Kingdom’s First Cardio-Oncology Service	23
Imaging Immune Checkpoint Inhibitor Myocarditis	23
Diet and Prevention of Cardiovascular Disease and Cancer	23
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	23
High-Sensitivity Troponin I	23
Full Issue PDF	23
Vascular Complications of Atrial Fibrillation in Patients With Cancer	22
CHA2DS2-VASc Score in Cardio-Oncology	22
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	22
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	22
Reply	21
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	21
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	21
Fluoropyrimidine Therapy in Gastrointestinal Cancer	20
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	20
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	20

Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	20
Low QRS Voltages in Cardiac Amyloidosis	20
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	20
FULL ISSUE PDF	19
Hearts on the Minds of Oncologists	19
To Adjudicate or Not Adjudicate	19
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	19
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	19
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	19
Cardiovascular Risk Assessment in Patients With Kidney Cancer	19
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	18
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	18
Full Issue PDF	18
Cancer Therapy–Related Cardiac Dysfunction	17
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	17
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	17
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	17
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure	16
Redefining Gamification for Cardiovascular Prevention in High-Risk Cancer Survivors	16
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	16
Navigating the Uncharted	15
Cardiovascular Considerations After Cancer Therapy	15
Reply	15
Guiding Treatment With Recovered CTRCD	15
Cardiovascular Care After Cancer	15
(Less) Time and Energy	14
Preventing Cancer Therapy–Related Cardiotoxicity	14
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	14
Reply	14
Addressing the Overlooked	13
Reassessing Troponin Surveillance in Immunotherapy	13
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	13
The Cause of Death in Patients With Cancer	13
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	13
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	13
Editorial Board	13
Clinical Practice Guidelines in Cardio-Oncology	13
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	13
Reply	13
Overcoming LGBTQI+ Disparities in Cardio-Oncology	12
Reply	12
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	12
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	12
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	12
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	12
Full Issue PDF	12
Editorial Board/Officers Page	12
Learning From Trials	12
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	12
Full Issue PDF	12
When Clot Is Tumor	12
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	12
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	12
The ESC Cardio-Oncology Guidelines	12
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	12
Reply	11
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	11
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	11
Reply	11
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage	11
Editorial Board	11
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	11
Assessing STEMI Outcomes in Patients With Cancer	10
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	10
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	10
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	10
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	10
Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy	10
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	10
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	10
Reply	10